AbbVie (ABBV) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance

AbbVie (NYSE: ABBV) reported Q4 EPS of $2.79, $0.02 better than the analyst estimate of $2.77. Revenue for the quarter came in at $14.3 billion versus the consensus estimate of $14.01 billion.

GUIDANCE:

AbbVie sees FY2024 EPS of $11.05-$11.25, versus the consensus of $11.24.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Health Canada approves AbbVie's Boey for frown line treatment
• Energy Fuels to acquire rare earth magnet maker VAC for $1.9 billion